90 phenotypes from 6 alleles in 7 genetic backgrounds

Allelic Composition Genetic Background	Annotated Term	Reference
Crhm1H/Crh+ involves: C3H/HeH * C57BL/6J	abnormal blood homeostasis	J:208708
	abnormal bone marrow morphology	J:208708
	abnormal corticosterone level	J:208708
	abnormal fat cell morphology	J:208708
	abnormal glucose homeostasis	J:208708
	abnormal hepatocyte morphology	J:208708
	abnormal homeostasis	J:208708
	abnormal urine homeostasis	J:208708
	decreased body weight	J:208708
	decreased bone mineral density	J:208708
	decreased bone mineralization	J:208708
	decreased bone ossification	J:208708
	decreased circulating osteocalcin level	J:208708
	decreased circulating parathyroid hormone level	J:208708
	decreased lean body mass	J:208708
	decreased osteoblast cell number	J:208708
	normal homeostasis/metabolism phenotype	J:208708
	hyperglycemia	J:208708
	impaired glucose tolerance	J:208708
	increased adrenal gland weight	J:208708
	increased adrenal gland zona fasciculata size	J:208708
	increased blood uric acid level	J:208708
	increased body weight	J:208708
	increased circulating alanine transaminase level	J:208708
	increased circulating alkaline phosphatase level	J:208708
	increased circulating aspartate transaminase level	J:208708
	increased circulating calcium level	J:208708
	increased circulating cholesterol level	J:208708
	increased circulating corticosterone level	J:208708
	increased circulating creatinine level	J:208708
	increased circulating glucagon level	J:208708
	increased circulating insulin level	J:208708
	increased circulating leptin level	J:208708
	increased circulating total protein level	J:208708
	increased circulating triglyceride level	J:208708
	increased total body fat amount	J:208708
	increased urine calcium level	J:208708
	increased urine corticosterone level	J:208708
	increased urine glucose level	J:208708
	increased urine protein level	J:208708
	insulin resistance	J:208708
	obese	J:208708
	polydipsia	J:208708
	polyuria	J:208708
	premature hair loss	J:208708
	thin skin	J:208708
	thin tail	J:208708
Crhtm1(cre)Zjh/Crhtm1(cre)Zjh involves: C57BL/6	no abnormal phenotype detected	J:151755
Crhtm1Maj/Crhtm1Maj involves: 129S2/SvPas * C57BL/6	abnormal adrenocorticotropin level	J:72196, J:102987
	abnormal body weight	J:105629
	abnormal cell-mediated immunity	J:98419
	abnormal circulating adrenaline level	J:105629
	abnormal circulating corticosterone level	J:54256, J:72196, J:90690, J:102987, J:105629
	abnormal circulating glucose level	J:102987, J:105629
	abnormal circulating hormone level	J:90690
	abnormal circulating noradrenaline level	J:105629
	abnormal club cell morphology	J:53721
	abnormal cytokine secretion	J:98419
	abnormal epidermis stratum corneum morphology	J:49863
	abnormal epidermis stratum granulosum morphology	J:49863
	abnormal food intake	J:105629
	abnormal inflammatory response	J:98419
	abnormal lung development	J:53721
	abnormal professional antigen presenting cell physiology	J:98419
	abnormal solitary pulmonary neuroendocrine cell morphology	J:53721
	abnormal surfactant composition	J:53721
	decreased circulating adrenaline level	J:102987
	decreased circulating corticosterone level	J:105629
	decreased circulating leptin level	J:105629
	decreased inflammatory response	J:72196, J:90690
	decreased susceptibility to experimental autoimmune encephalomyelitis	J:98419
	decreased T cell proliferation	J:98419
	increased circulating interleukin-6 level	J:72196
	increased mesenchymal cell proliferation involved in lung development	J:53721
	increased splenocyte number	J:98419
Crhtm1Maj/Crhtm1Maj involves: 129S2/SvPas * C57BL/6J	abnormal adrenal gland morphology	J:23082
	abnormal circulating corticosterone level	J:23082
	abnormal circulating glucose level	J:23082
	abnormal lung morphology	J:23082
	abnormal respiratory system physiology	J:23082
	decreased adrenal gland zona fasciculata size	J:23082
	maternal effect	J:23082
	normal nervous system phenotype	J:23082
	thick pulmonary interalveolar septum	J:23082
Crhtm2.1Maj/Crhtm2.1Maj Tg(Sim1-cre)1Lowl/? involves: 129S4/SvJae * C57BL/6 * FVB/N	abnormal adrenal gland secretion	J:238330
	adrenal gland atrophy	J:238330
	decreased adrenal gland weight	J:238330
	decreased anxiety-related response	J:238330
	decreased circulating adrenocorticotropin level	J:238330
	decreased circulating corticosterone level	J:238330
Crhtm2.2Maj/Crhtm2.2Maj involves: 129S4/SvJae * C57BL/6 * FVB/N	abnormal adrenal gland secretion	J:238330
	adrenal gland atrophy	J:238330
	decreased circulating corticosterone level	J:238330
	maternal effect	J:238330
Gt(ROSA)26Sortm1(Crh)Jde/Gt(ROSA)26Sortm1(Crh)Jde Tg(Camk2a-cre/ERT2)2Gsc/0 involves: 129S2/SvPas * C57BL/6J * FVB/N	increased anxiety-related response	J:176339
Gt(ROSA)26Sortm1(Crh)Jde/Gt(ROSA)26Sortm1(Crh)Jde Tg(Nes-cre)1Kln/0 involves: 129S2/SvPas * C57BL/6 * SJL	abnormal seizure response to pharmacological agent	J:140968
	decreased susceptibility to neuronal excitotoxicity	J:140968